CompletedPhase 2

To Compare the Efficacy of Weekly Azathioprine Pulse Versus Betamethasone Oral Mini-Pulse in the Treatment of Moderate to Severe Alopecia Areata

Pakistan60 participantsStarted 2023-03-01

Plain-language summary

Alopecia areata (AA) is an autoimmune condition characterized by non-scarring hair loss, ranging from minor patches to complete baldness. Given the variable effectiveness of existing treatments, this study aimed to compare the efficacy of weekly Azathioprine pulse (WAP) therapy against Betamethasone oral mini-pulse (BOMP) therapy in managing moderate to severe AA.

Who can participate

Age range16 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * aged 16-60 years * scalp area involvement of ≥ 15% by Alopecia Areata Exclusion Criteria: * used topical and intralesional treatment within last 1 month, * received systemic therapy or phototherapy within last three months, * anemia, leukocytosis, leukopenia, thrombocytopenia, deranged renal and liver function test * pregnant an lactating females * patients with contraindications to corticosteroids or Azathioprine

What they're measuring

Severity of Alopecia Tool (SALT) score

Timeframe: Clinical Assessment will be done monthly for 6 months

Trial details

NCT IDNCT06786689

SponsorSheikh Zayed Medical College

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2023-05-31

View on ClinicalTrials.gov More Alopecia Areata trials